Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies
Cancer Treatment Reviews · 2025
DOI: 10.1016/j.ctrv.2025.102925 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025. Verfasst von Teresa Alonso-Gordoa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: jmaroto@santpau.cat. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Immunotherapy has changed the management of localized clear cell renal cell carcinoma (ccRCC) since the approval of adjuvant pembrolizumab, which demonstrated significant improvements in disease-free survival (DFS) and overall survival (OS) in patients at intermediate and high risk of recurrence. This new approach impacts rescue strategies in patients who relapse after local treatment and during or after adjuvant pembrolizumab. Nevertheless, there is currently no robust scientific evidence on therapeutic decision-making in this clinical situation, representing an area for further debate and research. In this article, a group of experts from the Genitourinary Alliance for Research and Development (GUARD) have reviewed the available scientific evidence to establish the basis for therapeutic decision-making in patients with ccRCC who progress after adjuvant treatment with immunotherapy. Despite the lack of randomized clinical trials in this setting, this group of experts recommends classifying patients according to relapse volume (oligometastatic vs. polymetastatic), time to relapse and certain molecular characteristics. Rescue treatments beyond relapse should be individualized and might include locoregional treatments such as surgery or radiotherapy as well as antiangiogenic therapies in patients defined as resistant to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: jmaroto@santpau.cat.
- Medical- Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain. Electronic address: ganguera@santpau.cat.
- Urology Department, IDIVAL, Marqués de Valdecilla University Hospital, Santander, Spain. Electronic address: mariodominguezesteban@gmail.com.
- Laboratory of Translational Genomics and Targeted Therapies in Solid Tumours, Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Medicine Department, Barcelon…
- Oncology Pharmacy Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: hilario.martinez.barros@gmail.com.
- Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: javier.molinace@gmail.com.
Zitieren
APA
Alonso-Gordoa, T., Anguera, G., Domínguez-Esteban, M., Reig, Ò., Martínez-Barros, H., Molina-Cerrillo, J., Cruz, P., & Maroto, P. (2025). Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2025.102925
Vancouver
Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, et al. Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. Cancer Treatment Reviews. 2025. doi:10.1016/j.ctrv.2025.102925
BibTeX
@article{AlonsoGordoa2025,
author = {Alonso-Gordoa, Teresa and Anguera, Georgia and Domínguez-Esteban, Mario and Reig, Òscar and Martínez-Barros, Hilario and Molina-Cerrillo, Javier and Cruz, Patricia and Maroto, Pablo},
title = {Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies},
journal = {Cancer Treatment Reviews},
year = {2025},
doi = {10.1016/j.ctrv.2025.102925}
}
EUVIMED